Literature DB >> 9660987

Decreased accumulation or increased isoleucyl-tRNA synthetase activity confers resistance to the cyclic beta-amino acid BAY 10-8888 in Candida albicans and Candida tropicalis.

K Ziegelbauer1.   

Abstract

BAY 10-8888, a cyclic beta-amino acid, exerts its antifungal activity by inhibition of isoleucyl-tRNA synthetase activity after accumulation to a millimolar concentration inside the cell. We have selected and characterized BAY 10-8888-resistant Candida albicans mutants. Reduced BAY 10-8888 accumulation as well as increased isoleucyl-tRNA synthetase activity was observed in these mutants. Some of the mutants were cross-resistant to cispentacin, a structurally related beta-amino acid, while sensitivities to 5-fluorocytosine and fluconazole remained unchanged in all mutants. All except two in vitro-resistant mutants were pathogenic in a murine candidiasis model, and BAY 10-8888 failed to cure the infection. Furthermore, we have characterized BAY 10-8888 transport and isoleucyl-tRNA synthetase activity in several Candida tropicalis strains which showed MICs higher than those of other Candida strains. An analysis of the C. tropicalis strains revealed that intracellular concentrations of BAY 10-8888 were in the millimolar range, comparable to those for C. albicans. However, these isolates expressed isoleucyl-tRNA synthetase activities about fourfold higher than those for C. albicans. To test the possibility of resistance modeling, we determined the correlations between the intracellular concentration of BAY 10-8888, the specific activity of isoleucyl-tRNA synthetase, the number of free, i.e., noninhibited, isoleucyl-tRNA synthetase molecules/cell, and growth, assuming a linear relation. We found significant correlations between growth and the intracellular concentration of BAY 10-8888 and between growth and the number of free isoleucyl-tRNA synthetase molecules/cell, but not between growth and the specific activity of isoleucyl-tRNA synthetase.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9660987      PMCID: PMC105649     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Getting started with yeast.

Authors:  F Sherman
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

2.  Synthesis and antifungal activity of FR109615 analogs.

Authors:  H Ohki; Y Inamoto; K Kawabata; T Kamimura; K Sakane
Journal:  J Antibiot (Tokyo)       Date:  1991-05       Impact factor: 2.649

3.  FR109615, a new antifungal antibiotic from Streptomyces setonii. Taxonomy, fermentation, isolation, physico-chemical properties and biological activity.

Authors:  T Iwamoto; E Tsujii; M Ezaki; A Fujie; S Hashimoto; M Okuhara; M Kohsaka; H Imanaka; K Kawabata; Y Inamoto
Journal:  J Antibiot (Tokyo)       Date:  1990-01       Impact factor: 2.649

4.  Azole susceptibility and hyphal formation in a cytochrome P-450-deficient mutant of Candida albicans.

Authors:  N D Lees; M C Broughton; D Sanglard; M Bard
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

5.  Isogenic strain construction and gene mapping in Candida albicans.

Authors:  W A Fonzi; M Y Irwin
Journal:  Genetics       Date:  1993-07       Impact factor: 4.562

6.  Cispentacin, a new antifungal antibiotic. I. Production, isolation, physico-chemical properties and structure.

Authors:  M Konishi; M Nishio; K Saitoh; T Miyaki; T Oki; H Kawaguchi
Journal:  J Antibiot (Tokyo)       Date:  1989-12       Impact factor: 2.649

7.  Anti-Candida activity of cispentacin: the active transport by amino acid permeases and possible mechanisms of action.

Authors:  J O Capobianco; D Zakula; M L Coen; R C Goldman
Journal:  Biochem Biophys Res Commun       Date:  1993-02-15       Impact factor: 3.575

8.  SHR3: a novel component of the secretory pathway specifically required for localization of amino acid permeases in yeast.

Authors:  P O Ljungdahl; C J Gimeno; C A Styles; G R Fink
Journal:  Cell       Date:  1992-10-30       Impact factor: 41.582

9.  Glucan synthesis and its inhibition by cilofungin in susceptible and resistant strains of Candida albicans.

Authors:  L Angiolella; C Bromuro; N Simonetti; A Cassone
Journal:  J Med Vet Mycol       Date:  1992

10.  Mechanism of action of nikkomycin and the peptide transport system of Candida albicans.

Authors:  P J McCarthy; P F Troke; K Gull
Journal:  J Gen Microbiol       Date:  1985-04
View more
  7 in total

1.  In vitro activity and in vivo efficacy of icofungipen (PLD-118), a novel oral antifungal agent, against the pathogenic yeast Candida albicans.

Authors:  Andreja Hasenoehrl; Tatjana Galic; Gabrijela Ergovic; Natasa Marsic; Mihael Skerlev; Joachim Mittendorf; Ulrich Geschke; Axel Schmidt; Wolfgang Schoenfeld
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Dispersed disease-causing neomorphic mutations on a single protein promote the same localized conformational opening.

Authors:  Weiwei He; Hui-Min Zhang; Yeeting E Chong; Min Guo; Alan G Marshall; Xiang-Lei Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-07       Impact factor: 11.205

3.  Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Amy M Kelaher; Alia A Sarafandi; Diana Mickiene; Andreas H Groll; Tin Sein; John Bacher; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

4.  Cytocidal amino acid starvation of Saccharomyces cerevisiae and Candida albicans acetolactate synthase (ilv2{Delta}) mutants is influenced by the carbon source and rapamycin.

Authors:  Joanne M Kingsbury; John H McCusker
Journal:  Microbiology (Reading)       Date:  2009-12-17       Impact factor: 2.777

5.  Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Amy M Kelaher; Alia A Sarafandi; Tin Sein; Diana Mickiene; John Bacher; Andreas H Groll; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 6.  Amino Acid Metabolism and Transport Mechanisms as Potential Antifungal Targets.

Authors:  Matthew W McCarthy; Thomas J Walsh
Journal:  Int J Mol Sci       Date:  2018-03-19       Impact factor: 5.923

7.  Screening of Candida albicans GRACE library revealed a unique pattern of biofilm formation under repression of the essential gene ILS1.

Authors:  Anna Carolina Borges Pereira Costa; Raha Parvizi Omran; Tuana Oliveira Correia-Mesquita; Vanessa Dumeaux; Malcolm Whiteway
Journal:  Sci Rep       Date:  2019-06-24       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.